Download Unicorn Signals App

Powered By EquityPandit
Latest News

USFDA has issued warning letter to Mylan for Nashik facility

Food and Drug Administration Headquarters building in Silver Spring, MD. Photo by Alison Young/ USA TODAY [Via MerlinFTP Drop]

A warning letter has been issued by the US health regulator to Mylan for violations of good manufacturing norms, including data integrity lapses and failure of quality control at its Nashik facility.

The letter, that has been issued by the United States Food and Drug Administration (USFDA) to the Mylan Pharmaceuticals Inc President Rajiv Malik states that it had inspected the Nashik facility of the company from September 5 to 14, 2016.

It added that there were “significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals”, at the facility.

The letter said that “Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness and quality of the drugs you manufacture.”

Read EquityPandit’s Technical Analysis on Nifty Pharma

Get Daily Prediction & Stocks Tips On Your Mobile